Vaxart's Two Newest Independent Directors James Breitmeyer, M.D., Ph.D., and Kevin Finney Send Letter to Shareholders Ahead of 2026 Annual Meeting

Stock Information for Vaxart Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Vaxart Inc.

Vaxart to Showcase Oral Vaccine Platform and Strategic Vision at BIO 2026 and Taiwan Biotech Forum
Vaxart to Participate in BTIG Infectious Disease Day 2026
Vaxart Urges Shareholders to Vote "FOR" ALL Six of the Company's Highly Qualified Director Nominees on the WHITE Proxy Card TODAY
Vaxart Files Definitive Proxy Statement and Mails Letter to Shareholders
Vaxart Files Preliminary Proxy Statement and Issues Open Letter to Shareholders
Vaxart Provides Business Update and Reports First Quarter 2026 Financial Results
Vaxart to Host Stockholder Fireside Chat on May 8 at 4:30 p.m. ET
Vaxart Appoints James Breitmeyer, M.D., Ph.D., to Board of Directors

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.